Sjögren’s disease, not syndrome

2021 ◽  
Author(s):  
Alan N. Baer ◽  
Katherine M. Hammitt
Keyword(s):  
2020 ◽  
pp. 33-38
Author(s):  
E. Yu. Gan ◽  
L. P. Evstigneeva

Purpose of the study. Assessing the association between the life quality of patients with Sjogren’s Disease and ongoing therapy with various disease-modifying antirheumatic drugs.Material and methods. The study was conducted on the basis of the regional rheumatology center of the consultative diagnostic clinic of the Sverdlovsk Regional Clinical Hospital No. 1. This work is based on the results of a simultaneous study of 74 patients with primary Sjogren’s Disease (SD), distributed in three comparison groups receiving various disease-modifying antirheumatic drugs chlorambucil, methotrexate and hydroxychloroquine. The diagnosis of SD was carried out according to European-American criteria AECGC (2002) [18]. In order to analyze the quality of life of patients with SD, the 36-Item Short Form Health Survey (SF‑36) was used. Statistical data processing was carried out using Statistica 7.0 program.Results. Assessment of the quality of life of patients with SD, which is an integrative criterion of human health and well-being, revealed the absence of statistically significant differences (p > 0.05) on eight scales and two health components of the SF‑36 questionnaire in the analyzed groups that differ in the treatment of disease-modifying antirheumatic drugs chlorambucil, methotrexate and hydroxychloroquine.Conclusions. The obtained data indicate an equivalent quality of life in SD patients treated with different disease-modifying antirheumatic drugs methotrexate, chlorambucil and hydroxychloroquine, and therefore hydroxychloroquine can be considered as an alternative basic therapy in patients with SD with certain limitations and contraindications methotrexate and chlorambucil.


1994 ◽  
Vol 40 (1) ◽  
pp. 30-31
Author(s):  
Ye A Sycheva ◽  
Ts S Khein

Therapists, including rheumatologists, often forget that many autoimmune diseases are combined with endocrine pathology, in particular with thyroid pathology. These cases, according to the classification of N. Smith and A. Steinberg, belong to the 5th class - class E of autoimmune diseases, which includes conditions that manifest several autoimmune diseases, both organ-specific and organ-specific. In the literature, cases of combinations of endocrine diseases with non-endocrine autoimmune are described. It was noted that they are most often found in young women, which are associated with the X chromosome. We give our own observation of a patient with Sjogren's disease in combination with thyroid pathology.


2021 ◽  
Vol 25 (3) ◽  
pp. 35-40
Author(s):  
Maria O. Mohika Estepa ◽  
Nadezhda V. Muzhikina

Coronavirus infection, according to modern data, poses a threat not only to the respiratory system, in more than 15% of patients it can lead to cardiovascular complications, including in young and middle-aged people. COVID-19 is probably the trigger of a detailed clinical picture of chronic diseases occurring in a latent form. The article considers the case of sinus node dysfunction and polyneuropathy in a young patient after coronavirus infection against the background of concomitant diseases such as Sjogrens disease and Thompsons myotonia. To observe the dynamics of the three diseases, the timely organization of a multidisciplinary approach is important. It is necessary to consider all three diseases in the paradigm of the main and concomitant in order to timely and adequate therapy. Further study of the clinical features, therapeutic approaches and complications in patients with COVID-19 is required.


2015 ◽  
Vol 2015 (may14 1) ◽  
pp. bcr2014209076-bcr2014209076 ◽  
Author(s):  
A. Justet ◽  
S. Ottaviani ◽  
P. Dieude ◽  
C. Taille
Keyword(s):  

1972 ◽  
Vol 65 (2) ◽  
pp. 167-168 ◽  
Author(s):  
D J Grundy ◽  
Michael Hobsley
Keyword(s):  

1979 ◽  
Vol 82 (9) ◽  
pp. 899-904
Author(s):  
MASHIKO ITOGA ◽  
YASUSHI MURAKAMI ◽  
TOSHIAKI OUCHI ◽  
TAKESHI TOJO ◽  
TAKER NISHIKAWA

2019 ◽  
Vol 12 (5) ◽  
pp. e228876 ◽  
Author(s):  
Justine Serre ◽  
David Buob ◽  
Jean-Jacques Boffa

Hydroxychloroquine (HCQ) is largely prescribed as an immunomodulator to prevent systemic diseases flares in patients with systemic lupus erythematous, rheumatoid arthritis, Sjogren’s disease. Among reported side effects, HCQ can accumulate in lysosomes and induced phospholipidosis. Here, we report an HCQ-induced podocytopathy mimicking Fabry disease (FD). They share the same histological lesions: cytoplasmic vacuolisation of the podocytes and zebra bodies on light and electronic microscopy. FD has been ruled out by measuring enzymatic activity and genetic test. The persistence of proteinuria after immunological remission of a systemic disease treated with HCQ could suggest this HCQ-induced podocytopathy.


BMJ ◽  
1951 ◽  
Vol 1 (4718) ◽  
pp. 1302-1303 ◽  
Author(s):  
A. B. Harrington ◽  
H. A. Dewar
Keyword(s):  

1989 ◽  
Vol 2 (4) ◽  
pp. 609
Author(s):  
V.I. Vasilyev ◽  
A.S. Chicklikchi ◽  
S.K. Solovjev ◽  
M.N. Manoussakis ◽  
P. Katsikis

Sign in / Sign up

Export Citation Format

Share Document